[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100089663":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":7,"responsibleParty":15,"collaborators":17,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":25,"acronym":7,"eligibilityCriteria":26,"healthyVolunteers":22,"sex":27,"minAge":28,"maxAge":29,"enrollmentInfo":30,"targetDuration":7,"studyType":32,"phases":33,"briefSummary":35,"conditions":36,"keywords":38,"overallStatus":43,"whyStopped":7,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":7,"leadSponsor":50,"locationsCount":7},{"fullName":5,"class":6},"Novartis","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Vatalinib",[13],{"name":5,"affiliation":5,"role":14},"STUDY_CHAIR",{"type":7,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":16,"oldOrganization":5},"External Affairs",[18],{"name":19,"class":6},"Bayer","100089663","phase-1-a-drug-drug-interaction-study-of-oral-1250-mg-of-vatalinib-administered-under-fasting-and-fed-conditions-with-a-proton-pump-inhibitor-in-healthy-sterile-or-postmenopausal-female-volunteers-100089663",false,"NCT00426452","A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers","A Phase IB, Open Label, Single Center, Drug-drug Interaction Study of Oral 1250 mg of PTK787\u002FZK 222584 Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor (Omeprazole) in Healthy Sterile or Postmenopausal Female Volunteers","Inclusion criteria\n\n* Healthy female\n* Surgically sterile or post-menopausal\n* At least a weight of 50 kg and have a body mass index (BMI) ≤33.0\n* Non-smokers or those who smoke 25 cigarettes or less per day Exclusion criteria\n* Use of certain prescription and over the counter drugs\n* Having received an investigational drug within 30 days prior to dosing\n* Donation of plasma or donation or loss of whole blood prior to administration of the study medication\n* Any clinically significant laboratory tests\n* Abnormal cardiac function\n* A positive test for HIV, Hepatitis B or C\n* A positive alcohol test or drug test\n* Known allergy to Vatalinib or Omeprazole\n* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism and excretion or drugs.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply","FEMALE","35 Years","70 Years",{"count":31,"type":7},24,"INTERVENTIONAL",[34],"PHASE1","This study will determine the effect of acidic drugs such as proton-pump inhibitors on the pharmacokinetics of Vatalinib under fasting and fed conditions.",[37],"Healthy",[39,11,40,41,42],"Vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitor","Proton-pump inhibitors","Omeprazole","Healthy Postmenopausal Female Volunteers","COMPLETED","2009-11-18",{"date":46,"type":47},"2009-11-19","ESTIMATED",{"date":49,"type":7},"2006-07",{"name":5,"class":6}]